Analysis: The FDA's controversial strategy for evaluating new COVID boosters

Primary tabs

Analysis: The FDA's controversial strategy for evaluating new COVID boosters

Thu, 2022-08-18 09:05 — mike kraft

What's behind the FDA's controversial strategy for evaluating new COVID boosters Some scientists are alarmed that the agency plans to evaluate the next generation of boosters by reviewing mouse studies alone. Others say there's no time to waste waiting for human trials. NPR.org

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Analysis

Groups this Group Post belongs to:

- Private group -

Log in or register to post comments

Workflow history

Revision ID	Field name	Date	Old state	New state name	By	Comment	Operations
			No state	No state

Resilience System

Language

Anonymous's groups in this site

Your groups across all your sites

Recent Content

Recent Comments

Who's online

You are here

Analysis: The FDA's controversial strategy for evaluating new COVID boosters

Primary tabs

Analysis: The FDA's controversial strategy for evaluating new COVID boosters

Resilience System

User login

Search form

Language

Anonymous's groups in this site

Your groups across all your sites

Recent Content

Recent Comments

Who's online

You are here

Analysis: The FDA's controversial strategy for evaluating new COVID boosters

Primary tabs

Analysis: The FDA's controversial strategy for evaluating new COVID boosters